On May 15, 2026, Zenas BioPharma, Inc. disclosed the granting of 51,075 restricted stock units of the company's common stock to new employees joining the company. This move was made by the Compensation Committee of the company's Board of Directors as an inducement for the employees to start employment. Zenas, a clinical-stage global biopharmaceutical firm listed on Nasdaq as ZBIO, focuses on developing and commercializing innovative therapies for individuals with autoimmune diseases. The grant falls under Nasdaq Listing Rule 5635(c)(4) and aims to support the company's growth in this sector.